Literature DB >> 27543437

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.

Taimur Sher1, Brooke Fenton1, Adnan Akhtar2, Morie A Gertz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27543437     DOI： 10.1182/blood-2016-06-722496

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  23 in total

1.  Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.

Authors:  Eli Muchtar; Morie A Gertz; Shaji K Kumar; Martha Q Lacy; David Dingli; Francis K Buadi; Martha Grogan; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Amie Fonder; Miriam Hobbs; Yi Lisa Hwa; Wilson Gonsalves; Rahma Warsame; Taxiarchis V Kourelis; Stephen Russell; John A Lust; Yi Lin; Ronald S Go; Steven Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Blood       Date:  2017-01-26       Impact factor: 22.113

Review 2.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

3.  Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function.

Authors:  Paolo Milani; Marco Basset; Paola Curci; Andrea Foli; Rita Rizzi; Mario Nuvolone; Raffaella Guido; Loreto Gesualdo; Giorgina Specchia; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood Adv       Date:  2020-04-14

4.  Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Edward N Libby; Stephen M Ansell; M Lia Palomba; Kirsten Meid; Catherine A Flynn; Carly Leventoff; Christopher B Hergott; Tomasz Sewastianik; Elizabeth A Morgan; Ruben Carrasco; Jonathan R Fromm; Guang Yang; Zachary Hunter; Steven P Treon
Journal:  Blood Adv       Date:  2020-10-27

Review 5.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Novel pharmacotherapies for cardiac amyloidosis.

Authors:  Kevin M Alexander; Avinainder Singh; Rodney H Falk
Journal:  Pharmacol Ther       Date:  2017-06-22       Impact factor: 12.310

7.  Clinical trials evaluating potential therapies for light chain (AL) amyloidosis.

Authors:  Eli Muchtar; Morie A Gertz
Journal:  Expert Opin Orphan Drugs       Date:  2017-04-27       Impact factor: 0.694

Review 8.  Daratumumab for the treatment of AL amyloidosis.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2018-07-22

Review 9.  Amyloid and the Heart.

Authors:  Aaron M Wolfson; Kevin S Shah; Jignesh K Patel
Journal:  Curr Cardiol Rep       Date:  2019-12-03       Impact factor: 2.931

Review 10.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Blood Cancer J       Date:  2021-05-15       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.